CMND 6-K
Clearmind Medicine Inc. (CMND)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: July 2025
Commission file number: 001-41557
CLEARMINDMEDICINE INC.
(Translation of registrant’s name into English)
101 – 1220 West 6th Avenue
Vancouver, British Columbia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
Attached hereto and incorporated herein is the Registrant’s press release issued on July 15, 2025, titled “Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled”.
The first five paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
1
EXHIBIT INDEX
| Exhibit No. | |
|---|---|
| 99.1 | Press release titled: “Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled” |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Clearmind Medicine, Inc. | ||
|---|---|---|
| (Registrant) | ||
| Date: July 15, 2025 | By: | /s/ Adi Zuloff-Shani |
| Name: | Adi Zuloff-Shani | |
| Title: | Chief Executive Officer |
3
Exhibit 99.1
Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled
Vancouver, Canada, July 15, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the expansion of its Phase I/IIa clinical trial for CMND-100, its proprietary MEAI-based oral treatment candidate for Alcohol Use Disorder (AUD), with the activation of additional site at Johns Hopkins University School of Medicine and the enrollment of the first participant at this clinical site.
The trial is designed to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, with preliminary efficacy indicators assessing its potential to reduce alcohol cravings and consumption.
This expansion comes shortly after the Company announced the enrollment of its first participant at the Yale School of Medicine, reinforcing the positive momentum in Clearmind’s clinical development program.
The continuation of enrollment further expands Clearmind’s international clinical network and strengthens the growing interest in CMND-100 as a potentially groundbreaking treatment for AUD.
The Phase I/IIa clinical trial is a multinational, multicenter, single- and multiple-dose study that aims to establish the safety and optimal dosing of CMND-100. The trial will also explore early signals of efficacy, including reductions in alcohol consumption and cravings, which could pave the way for further development of this groundbreaking therapy.
“Each new clinical site we activate and each new participant we enroll brings us one step closer to validating CMND-100’s potential to redefine the treatment landscape for AUD,” said Dr. Adi Zuloff-Shani, CEO of Clearmind. “This expansion reflects both the scientific community’s interest in our approach and our commitment to accelerating progress for patients in need of better solutions.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
Telephone: (604) 260-1566
General Inquiries
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains“forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securitieslaws. Words such as “expects,” “anticipates,” “intends,” “plans,”“believes,” “seeks,” “estimates” and similar expressions or variations of such words areintended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses thegrowing interest in CMND-100 as a potentially groundbreaking treatment for Alcohol Use Disorder, how the continued enrollmentfurther expands Clearmind’s international clinical network, CMND-100’s potential to redefine the treatment landscape forAlcohol Use Disorder and its commitment to accelerating progress for patients in need of better solutions. Forward-lookingstatements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many ofwhich, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in goodfaith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, andactual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-lookingstatements are subject to risks and uncertainties that could cause actual performance or results to differ materially from thoseexpressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company,reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission(“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for thefiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of thedate the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results,subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information exceptto the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, noinference should be drawn that the Company will make additional updates with respect thereto or with respect to otherforward-looking statements. References and links to websites have been provided as a convenience, and the information contained onsuch websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-partywebsites.